A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211 in Healthy Obese Subjects
Phase of Trial: Phase I
Latest Information Update: 04 May 2018
At a glance
- Drugs HM-15211 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Hanmi Pharmaceutical
- 27 Apr 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
- 27 Apr 2018 Status changed from not yet recruiting to recruiting.
- 22 Dec 2017 New trial record